Communiqués de presse MaaT Pharma annonce le lancement d’une nouvelle campagne de collecte et de production pour son portefeuille de biothérapies à base de microbiome La nouvelle campagne de collecte soutiendra le développement clinique futur du portefeuille de biothérapies à…MaaT Pharmaaoût 20, 2020
Communiqués de presse MaaT Pharma Appoints Claude Bertrand, Servier’s Executive Vice President of R&D, as Independent Board Member and Welcomes New Chief Medical Officer John Weinberg Lyon, France, July 16, 2020 – MaaT Pharma announced today the appointment of Claude Bertrand,…MaaT Pharmajuillet 16, 2020
Communiqués de presse MaaT Pharma annonce la nomination de Savita Bernal en tant que Chief Business Officer ---MaaT Pharma renforce son équipe de direction en ajoutant une expertise en termes de développement…MaaT Pharmamai 25, 2020
Communiqués de presse MaaT Pharma Announces Formation of Its GvHD-focused Scientific Advisory Board to Support Development of Microbiome Restoration Therapeutics in Hemato-oncological Indications Lyon, France, May 12, 2020 – MaaT Pharma announced today the appointment of leading international…MaaT Pharmamai 22, 2020
Communiqués de presse MaaT Pharma Annonce 18 millions d’euros de Financement Série B pour l’Expansion de son Développement Clinique de Médicaments Biologiques « Microbiote » Lyon, le 5 février 2020 - MaaT Pharma annonce aujourd'hui une levée de fonds de…MaaT Pharmafévrier 4, 2020
Communiqués de presse MaaT Pharma Announces €18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics Lyon, France, February 5, 2020 – MaaT Pharma announced today an €18 million Series B…MaaT Pharmajanvier 31, 2020
Communiqués de presse MaaT Pharma announces the presentation of data with its Lead Microbiota Biotherapeutic in intestinal GvHD at 61st American Society of Hematology (ASH) Annual Meeting Lyon, France, November 6, 2019 – MaaT Pharma announced today that a poster will…MaaT Pharmanovembre 6, 2019
Communiqués de presse MaaT Pharma Expands Executive Team to Strengthen Corporate Development and Accelerate Expansion of Microbiome Data Science Platform GutPrint Jean-Marc Renard, MS, MBA, joins as Chief Business Officer Emmanuel Prestat, PhD, joins as Computational…MaaT Pharmaseptembre 10, 2019
Communiqués de presse MaaT Pharma Completes Third Positive DSMB Assessment Setting High Safety Standard for Human Intestinal Microbiome Whole Ecosystem-Based Therapeutics Independent Data Safety Monitoring Board (DSMB) confirms continuation of Phase II HERACLES study in acute…MaaT Pharmajuin 24, 2019
Communiqués de presse MaaT Pharma Completes Third Positive DSMB Assessment Setting High Safety Standard for Human Intestinal Microbiome Whole Ecosystem-Based Therapeutics Independent Data Safety Monitoring Board (DSMB) confirms continuation of Phase II HERACLES study in acute…MaaT Pharmajuin 24, 2019